News
HAE
61.95
+2.43%
1.47
Haemonetics Is Maintained at Outperform by Mizuho
Dow Jones · 2d ago
Haemonetics Price Target Cut to $70.00/Share From $80.00 by Mizuho
Dow Jones · 2d ago
Mizuho Maintains Outperform on Haemonetics, Lowers Price Target to $70
Benzinga · 2d ago
Haemonetics price target lowered to $70 from $80 at Mizuho
TipRanks · 2d ago
Haemonetics price target lowered to $84 from $88 at BTIG
TipRanks · 2d ago
BTIG Reaffirms Their Buy Rating on Haemonetics (HAE)
TipRanks · 2d ago
Weekly Report: what happened at HAE last week (0406-0410)?
Weekly Report · 2d ago
Haemonetics (HAE) Is Up 5.7% After FDA Expands VASCADE MVP XL Labeling for Larger EP Sheaths
Simply Wall St · 04/08 19:26
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Weakness?
Simply Wall St · 04/07 11:31
Weekly Report: what happened at HAE last week (0330-0403)?
Weekly Report · 04/06 09:47
1 Value Stock on Our Buy List and 2 Facing Headwinds
Barchart · 04/06 04:14
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
PR Newswire · 04/01 20:05
Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27
TipRanks · 03/31 10:36
Is Haemonetics (HAE) Leveraging VASCADE MVP XL’s FDA Expansion To Deepen Its EP Moat?
Simply Wall St · 03/30 23:06
Haemonetics Receives FDA Approval To Expand Labeling For VASCADE MVP XL Venous Vascular Closure System
Benzinga · 03/30 20:18
Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system
TipRanks · 03/30 20:17
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
PR Newswire · 03/30 20:15
Weekly Report: what happened at HAE last week (0323-0327)?
Weekly Report · 03/30 09:47
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness
Simply Wall St · 03/26 21:08
Haemonetics Becomes Oversold (HAE)
NASDAQ · 03/25 20:29
More
Webull provides a variety of real-time HAE stock news. You can receive the latest news about Haemonetics Corp Mass through multiple platforms. This information may help you make smarter investment decisions.
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.